3 results
Approved WMOCompleted
The primary objective is to assess long-term safety of study drug(s) in subjects who are enrolled in Eisai-sponsored lenvatinib studies.
Approved WMOCompleted
The primary objective of the study is to evaluate the percentage of subjects with at least 35%spleen volume reduction in the fedratinib and the BAT arms.The secondary objectives are:• To evaluate the percentage of subjects with at least 50%…
Approved WMORecruiting
The objective of this study is to investigate the safety and effectiveness of different combinations of cancer immunotherapies compared to either Nivolumab or Ipilimumab, as determined by comparing the Overall Response Rate, at 24 weeks in patients…